Introduction: Recurrent urinary tract infections (UTI) are a common clinical problem in kidney
transplant recipients. Due to the complex urological anatomy derived from the implantation …

Kidney transplantation represents the gold standard treatment option for patients with end-
stage renal disease. Improvements in surgical technique and pharmacologic treatment have …

Background Polycystic kidney disease (PKD) accounts for approximately 15% of kidney
transplants, but long-term outcomes in patients with PKD who have received a kidney …

Background and objectives: For patients with end-stage renal disease (ESRD), the best
replacement therapy is renal transplant (RTx) to ensure life with good quality. Autosomal …

These guidelines address the management of patients with autosomal dominant polycystic
kidney disease who are candidates for kidney and/or liver transplantation. They include …

Infectious complications after solid organ transplantation (SOT) are often more severe and
remain a diagnostic challenge due to vague and atypical clinical presentations. Diagnostic …

常染色体显性多囊肾病(ADPKD) 是一种常见的单基因遗传性肾病, 可进展为终末期肾病(ESRD).
ADPKD 患者常反复发生囊内感染, 抗生素治疗所产生的耐药性问题日益突出 …

免疫抑制剂在常染色体显性遗传性多囊肾患者肾移植术后的应用- PMC Back to Top Skip to main
content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main …

African Americans (AA) are disproportionately affected by end-stage renal disease (ESRD)
and have worse outcomes following renal transplantation. Autosomal dominant polycystic …

Background & Aims: Autosomal dominant polycystic kidney disease (ADPKD) is the most
common hereditary kidney disease with a prevalence of 1 in 1000 people. The …